The clinical trial is for men, with or without a diagnosis of prostate cancer, who are about to undergo a routine prostate-specific antigen (PSA) test.
   
The purpose of this study is to see if a PSA value derived from the Point of Care Rapid Test for is similar to the value obtained from a certified laboratory. 
   
Participants who are visiting their physician to have their blood drawn to measure a PSA value will, within 1 hour of the blood test, also have a finger stick blood draw with a drop of blood placed on the measurement strip. 

This is a clinical trial for adults who have been diagnosed with Melanoma or Non-Small Cell Lung Cancer (NSCLC).

The purpose of this study is to test the safety and efficacy of an investigational drug RP1 when it is injected into a tumor on its own as well as in combination with nivolumab for the treatment of certain types of solid tumors. 

This is a clinical trial for adult men with progressive metastatic castration resistant prostate cancer.
   
The purpose of the initial phase I portion of this study is to find a dose level and administration schedule of the study drug, 225Ac-J591 plus 177Lu-PSMA-I&T that can be given without severe side effects. Following selection of the proper dose for each treatment regimen, the purpose of the phase II portion of the study is to test if the regimen of 225Ac-J591 plus 177Lu-PSMA-I&T leads to treatment response. 
   

This is a clinical trial for adult men diagnosed with progressive metastatic castration-resistant prostate cancer. 
   
The main purpose of this study is to evaluate the maximum tolerated and recommended dose of pembrolizumab and an androgen-receptor pathway inhibitor with or without the investigational drug 225Ac-J591 to see what its side effects are and if it works for this type of cancer.

This is a clinical trial for adult men with metastatic castrate resistant prostate cancer. The main purpose of this study is to evaluate the safety of the investigational drug Cabozantinib to see what its side effects are and if it works for this type of cancer.
   

This is a clinical trial for adults with metastatic squamous cell carcinoma of the esophagus.
   
The purpose of this study is to test two treatment regimens in people with advanced esophageal cancer to see how well they work to stop the cancer as well as to determine whether one treatment regimen is more effective than the other. The two treatment regimens being evaluated are lenvatinib + pembrolizumab with chemotherapy followed by lenvatinib + pembrolizumab compared to pembrolizumab with chemotherapy.
   

The purpose of this study is to find out whether the investigational study drug, relacorilant, is safe and effective in treating participants with hypercortisolism caused by adrenal adenomas or adrenal hyperplasia which is associated with elevated glucose levels, high blood pressure, or both. 

This is a study for women and men who are 18 years old and above and have been diagnosed with cirrhosis (scarring of the liver). This study is being conducted to identify things that contribute to keeping people healthy when they are living with liver cirrhosis.
  

This is a research study to test the safety of the investigational combination of tazemetostat and venetoclax for patients with non-Hodgkin lymphoma (NHL) whose disease has returned after having received prior treatment (relapsed), or whose disease has failed to respond to prior treatments (refractory).

This study will find the highest dose of venetoclax that can be given with tazemetostat without causing severe side effects. Both of these medications have been studied in patients with lymphoma and have been shown to be safe, however, they have not been used in combination.

The purpose of this study is to determine whether an experimental drug called AZD9833 is better at treating breast cancer characterized by the development of an ESR1 mutation than the standard of care (SoC) combination of an aromatase inhibitor and a CDK4/6 inhibitor.

An experimental drug is one that is being tested and is not yet approved by the United States Food and Drug Administration (FDA).